Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Report 2026

The endoscopic retrograde cholangiopancreatography (ercp) market size has grown strongly in recent years. It will grow from $1.86 billion in 2025 to $2.03 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to gallstone prevalence, aging population, gastrointestinal disease burden, hospital endoscopy expansion, imaging-guided procedures.

The endoscopic retrograde cholangiopancreatography (ercp) market size is expected to see strong growth in the next few years. It will grow to $2.79 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to advanced endoscopic training, early pancreatic diagnosis, therapeutic procedure growth, hospital infrastructure upgrades, minimally invasive care demand. Major trends in the forecast period include rising incidence of biliary disorders, increased use of therapeutic endoscopy, growth in minimally invasive GI procedures, expansion of advanced endoscopy units, focus on early diagnosis of pancreatic diseases.

The rising prevalence of gastrointestinal conditions is expected to drive the growth of the endoscopic retrograde cholangiopancreatography (ERCP) market in the coming years. Gastrointestinal conditions encompass a wide range of disorders affecting the GI tract, which includes the mouth, esophagus, stomach, small intestine, large intestine (colon), rectum, and anus, as well as accessory organs such as the liver, gallbladder, and pancreas. The increasing occurrence of these conditions is influenced by factors such as dietary changes, an aging population, antibiotic use, lifestyle habits, and environmental exposures. ERCP provides a minimally invasive approach to diagnose and treat problems within the bile and pancreatic ducts, including gallstones, strictures, tumors, and infections. For example, in January 2024, the American Cancer Society, a US-based non-profit organization, estimated approximately 26,890 new cases of stomach cancer in the United States, with around 10,880 deaths expected from this disease. As a result, the growing prevalence of gastrointestinal conditions is contributing to the expansion of the ERCP market.

Leading companies in the ERCP market are developing innovative technologies, such as cholangioscope direct visualization systems, to deliver high-resolution, direct imaging of the bile and pancreatic ducts. The cholangioscope system is a medical device that enables advanced visualization during ERCP procedures, enhancing both diagnosis and therapeutic interventions. For instance, in July 2024, Penlon Limited, a UK-based medical device manufacturer, launched the VedVision Cholangioscope Direct Visualization System. This advanced device provides high-resolution imaging of the bile and pancreatic ducts and features a 2 mm accessory channel and a dedicated guidewire channel for secure access. It is supported by a comprehensive range of accessories, including biopsy forceps, stone extraction baskets, cytology brushes, and polypectomy snares.

In April 2025, Medtronic Plc, a US-based medical technology company specializing in devices for ERCP procedures, partnered with Dragonfly Endoscopy Inc. to distribute the Dragonfly Pancreaticobiliary System in the United States. This partnership combines their expertise to enhance precision, visualization, and safety during ERCP procedures. Medtronic and Dragonfly Endoscopy aim to leverage their respective strengths, integrating Medtronic’s extensive commercialization and clinical support network with Dragonfly Endoscopy’s advanced pancreaticobiliary imaging and intervention technology. The collaboration provides gastroenterologists and surgeons with a comprehensive solution that improves visualization, precision, and safety in ERCP procedures, ultimately enhancing patient outcomes. Dragonfly Endoscopy Inc. is a US-based company that develops pancreaticobiliary endoscopy systems and oversees US distribution of the Dragonfly Pancreaticobiliary System.

Major companies operating in the endoscopic retrograde cholangiopancreatography (ercp) market are Medtronic plc, Fujifilm Holdings Corporation, Siemens Healthineers AG, Stryker Corporation, Boston Scientific Corporation, B. Braun Melsungen AG, Olympus Corporation, Ottomed Endoscopy, W. L. Gore & Associates Inc., Streis plc, Cook Group, KARL STORZ SE & Co. KG, CONMED Corporation, PENTAX Medical Inc., AMBU Inc., Samsung Medison Co. Ltd., Medi-Globe GmbH, Telemed System Inc., Micro-Tech Endoscopy Inc., Hobbs Medical Inc., Shaili Endoscopy Pvt. Ltd.

North America was the largest region in the endoscopic retrograde cholangiopancreatography (ERCP) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endoscopic retrograde cholangiopancreatography (ercp) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the endoscopic retrograde cholangiopancreatography (ercp) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the ERCP market by increasing costs of imported endoscopes, visualization systems, and endotherapy devices. Hospitals and specialty clinics in developed regions are most affected due to dependence on imported equipment. These tariffs increase procedural costs by raising equipment procurement and accessory expenses, affecting affordability of advanced biliary and pancreatic interventions. However, they encourage local production of endoscopic devices, strengthening regional device manufacturing.

The endoscopic retrograde cholangiopancreatography (ercp) market research report is one of a series of new reports that provides endoscopic retrograde cholangiopancreatography (ercp) market statistics, including endoscopic retrograde cholangiopancreatography (ercp) industry global market size, regional shares, competitors with a endoscopic retrograde cholangiopancreatography (ercp) market share, detailed endoscopic retrograde cholangiopancreatography (ercp) market segments, market trends and opportunities, and any further data you may need to thrive in the endoscopic retrograde cholangiopancreatography (ercp) industry. This endoscopic retrograde cholangiopancreatography (ercp) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Endoscopic retrograde cholangiopancreatography (ERCP) is a medical technique that combines endoscopy with X-ray imaging to diagnose and treat disorders of the bile ducts, gallbladder, and pancreas. The procedure involves guiding a flexible, illuminated tube (endoscope) through the mouth into the small intestine, enabling physicians to examine these organs and manage problems such as blockages or stones.

The key products used in ERCP include endoscopes, endotherapy devices, visualization systems, and energy devices. Endoscopes are flexible tubes fitted with a light and camera, allowing physicians to visualize the internal digestive tract during procedures like ERCP. The procedure addresses various disease indications, including gastroesophageal reflux disease (GERD), gastrointestinal cancers, Barrett’s esophagus, bile duct disorders, peptic ulcer disease, Crohn’s disease, intestinal pseudo-obstruction, Ogilvie syndrome, and others. ERCP is applied in several interventions, such as biliary sphincterotomy, biliary dilatation, biliary stenting, pancreatic sphincterotomy, pancreatic duct dilatation, and pancreatic duct stenting. The procedure is performed by various end users, including hospitals, clinics, ambulatory surgical centers, and others.

The endoscopic retrograde cholangiopancreatography (ERCP) market consists of revenues earned by entities by providing services such as diagnostic services, therapeutic services, post-operative, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The endoscopic retrograde cholangiopancreatography (ERCP) market also includes sales of biliary stents, guidewires, and catheters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.